Package Insert: Information for the User
LUMIGAN 0.1mg/ml, eye drops solution
bimatoprost
Read this package insert carefully before starting to use the medication, as it contains important information for you.
1.What is LUMIGAN 0.1 mg/ml and for what it is used
2.What you need to know before starting to use LUMIGAN 0.1 mg/ml
3.How to use LUMIGAN 0.1 mg/ml
4.Possible adverse effects
5.Storage of LUMIGAN 0.1 mg/ml
6.Contents of the package and additional information
LUMIGAN is a medication for glaucoma. LUMIGAN belongs to a group of medications called prostamides.
LUMIGAN eye drops are used to reduce high eye pressure. LUMIGAN can be used alone or with other eye drops called beta-blockers that also reduce pressure.
The eye contains a clear, watery liquid that keeps the inside of the eye. This liquid drains continuously out of the eye and new liquid is generated to replace it. If the liquid does not drain quickly enough, the pressure inside the eye increases. LUMIGAN acts by increasing the drainage of the liquid. This reduces the pressure inside the eye. If this pressure is not reduced, it could cause a disease called glaucoma and damage your vision.
Warnings and precautions:
Consult your doctor or pharmacist before starting to use LUMIGAN 0.1 mg/ml
During treatment, LUMIGAN may cause aloss of fat around the eye that can cause deepening of the eyelid crease, sunken eyes (enophthalmos), drooping eyelids (ptosis), stretching of the skin around the eye (dermatochalasis involution) and that the white lower part of the eye becomes more visible (inferior scleral exposure). The changes are usually mild, but if they worsen, they may affect your field of vision. The changes may disappear if you stop using LUMIGAN. LUMIGAN may also cause darkening and growth of eyelashes, as well as darkening of the skin around the eyelid. It may darken the color of the iris. These changes may be permanent and more noticeable if only one eye is being treated.
Children and adolescents
LUMIGAN has not been studied in patients under 18 years of age and should not be used in patients under 18 years of age.
Other medications and LUMIGAN:
Inform your doctor or pharmacist if you are using, have used recently or may need to use any other medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medication.
LUMIGAN may pass into breast milk, so you should not use it if you are breastfeeding.
Driving and operating machinery:
After instilling LUMIGAN, you may experience blurred vision for a short period of time. Do not drive or operate machinery until your vision clears.
LUMIGAN 0.1 mg/ml contains benzalkonium chloride
This medication contains 0.6 mg of benzalkonium chloride in each 3 ml of solution, which is equivalent to 0.2 mg/ml.
Do not use the eye drops when wearing contact lenses. Benzalkonium chloride, the preservative in Lumigan, can be absorbed by soft contact lenses and may alter the color of the lenses. Remove your contact lenses before using this medication and wait 15 minutes before reinserting them. Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other corneal (front transparent part of the eye) diseases. Consult your doctor if you feel a strange sensation, burning or pain in the eye after using this medication.
Follow exactly the medication administration instructions indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.
LUMIGAN should be used only in the eye. The recommended dose is one drop of LUMIGAN in each eye that requires treatment, once a day, in the late afternoon.
If you use LUMIGAN with another eye medication, wait at least five minutes between the use of LUMIGAN and the other eye medication.
Do not use the medication more than once a day, as it may reduce the effectiveness of the treatment.
Usage Instructions:
Do not use the container if the protective seal is broken before using it for the first time.
Wipe away any excess that may run down your cheek.
If the drop falls outside the eye, try again.
To help prevent infections and eye injuries, prevent the tip of the container from touching the eye or any other surface. Replace the cap and close the container immediately after use.
If you use moreLUMIGAN 0.1 mg/mlthan you should
If you use more LUMIGAN than you should, it is unlikely to cause any serious harm. Apply the next dose at the usual time. If you are concerned, talk to your doctor or pharmacist.
If you forget to useLUMIGAN 0.1 mg/ml
If you forget to apply LUMIGAN, use one drop as soon as you remember and return to your regular routine. Do not apply a double dose to compensate for the missed dose.
If you interrupt treatment with LUMIGAN 0.1 mg/ml
LUMIGAN should be used daily for it to work properly. If you stop using LUMIGAN, the pressure inside the eye may increase, so consult your doctor before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
These may affect 1 or more patients in every 10
These may affect between 1 and 9 patients in every 100
That affect the eye
That affect the skin
Rare side effects
These may affect between 1 and 9 patients in every 1000
That affect the eye
That affect the body
Side effects of unknown frequency
That affect the eye
That affect the body
Other side effects reported with eye drops containing phosphate
In very rare cases, some patients with severe damage to the transparent layer in the front of the eye (the cornea) have developed cloudy spots in the cornea due to the accumulation of calcium during treatment.
Reporting of side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect that does not appear in this leaflet. You can also report them directly throughthe national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label of the container and on the box after EXP. The expiration date is the last day of the month indicated.
You should discard the container, at the latest, four weeks after having opened it for the first time, even if there are still some drops left. This will help prevent infections. To remember, write the date you opened the container in the space provided on the box.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment.
Composition of LUMIGAN 0.1 mg/ml
Appearance of LUMIGAN 0.1 mg/ml and contents of the container
LUMIGAN is a colorless, transparent eye drop solution in a container that contains 1 or 3 plastic bottles, each with a screw cap. The contents of the bottle only reach approximately half and each bottle contains 3 ml of solution. The contents are sufficient for 4 weeks of treatment. Some container sizes may only be marketed.
Marketing authorization holder and manufacturer:
AbbVie Deutschland GmbH & Co. KG
Knollstraße
67061 Ludwigshafen
Germany
For more information about this medication, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien Luxembourg/Luxemburg/Nederland Allergan n.v. Tel: +32 (0)2 351 24 24 | Ísland Actavis Pharmaceuticals Iceland ehf. Phone: +354 550 3300 | |
.: +359 (0) 800 20 280 | Italia Allergan S.p.A Tel: +39 06 509 562 90 | |
Ceská republika Allergan CZ s.r.o. Tel: +420 800 188 818 | Latvija Allergan Baltics UAB Tel: +371 676 60 831 | |
Danmark/Norge/Suomi/Finland/Sverige Allergan Norden AB Phone: 4580884560 (DK) +47 80 01 04 97 (NO) +358 800 115 003 (FI) +46 (0)8 594 100 00 (SE) | Lietuva Allergan Baltics UAB Tel: +370 520 207 777 | |
Deutschland Pharm-Allergan GmbH Tel: +49 69 92038 1050 | Magyarország Allergan Hungary Kft. Tel: +36 800 100 101 | |
Eesti Allergan Baltics UAB Tel: +372 634 6109 | Österreich Pharm-Allergan GmbH Tel: +43 1 99460 6355 | |
Ελλ?δα/Κ?προς Allergan Hellas Pharmaceuticals S.A. Phone: +30 210 74 73 300 | Polska Allergan Sp. z o.o. Tel: +48 22 256 37 00 | |
España Allergan S.A.Tel: +34 91 807 6130 | Portugal Profarin Lda. Tel: +351 21 425 3242 | |
France Allergan France SAS Tel: +33 (0)1 49 07 83 00 | România Allergan S.R.L. Tel.: +40 21 301 53 02 | |
Hrvatska Ewopharma d.o.o. Tel: +385 1 6646 563 | Slovenija Ewopharma d.o.o. Tel: +386 (0) 590 848 40 | |
Ireland/MaltaAllergan Pharmaceuticals Ireland Tel: +353 1800 931 787 (IE) +356 27780331 (MT) | Slovenská republika Allergan SK s.r.o. Tel: +421 800 221 223 United Kingdom Allergan Ltd Tel: +44 (0) 1628 494026 |
Last update of this leaflet:
The detailed information about this medication is available on the website of the European Medicines Agencyhttp://www.ema.europa.eu//
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.